Drug intelligence / Profile preview

ZXBT-1158

Development stage: Unknown
Lead developer: Dongguan Zhenxing-Beite Medicine Technology
Modality: Small Molecules
Administration: Oral

Overview

ZXBT-1158 is a potent and selective small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Dongguan Zhenxing Beite Pharmaceutical Technology. It is designed to target the B-cell receptor (BCR) signaling pathway, which is essential for the survival and proliferation of malignant B cells. The drug is primarily being investigated for the treatment of various B-cell malignancies, including B-cell lymphoma, leukemia, and primary central nervous system lymphoma (PCNSL). Clinical trials are currently evaluating its safety, tolerability, and efficacy in patients with relapsed or refractory B-cell neoplasms, where it aims to provide a targeted therapeutic option by disrupting oncogenic signaling.

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on ZXBT-1158.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZXBT-1158.

Explore the full profile